Spray Venture Partners

Spray Venture Partners is a venture capital firm based in Newton, United States, that specializes in investing in early-stage companies within the healthcare technology sector. The firm is dedicated to providing both capital and expertise to emerging businesses, particularly those led by clinical and technical founders. Spray Venture Partners collaborates closely with these founders to develop, market, and deploy innovative technologies aimed at addressing significant unmet healthcare needs. The firm concentrates its efforts on companies involved in healthcare technology, diagnostic solutions, and therapeutic technologies, supporting the advancement of solutions that can transform patient care and improve health outcomes.

Daniel Cole

General Partner

Kevin Connors

Founder and General Partner

30 past transactions

Conventus Orthopaedics

Venture Round in 2013
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Tryton Medical

Venture Round in 2013
Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Direct Flow Medical

Venture Round in 2012
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Solace Therapeutics

Venture Round in 2012
Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

PneumRx

Venture Round in 2011
PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

Tryton Medical

Series D in 2010
Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

TearScience

Series C in 2010
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Barricaid

Venture Round in 2010
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Direct Flow Medical

Series C in 2009
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Interlace Medical

Series C in 2009
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Facet Solutions

Debt Financing in 2009
Facet Solutions is a medical device company based in Hopkinton, Massachusetts, established in 2003. The company specializes in developing surgical devices aimed at treating degenerative spinal disorders, particularly those related to facet joints. Facet Solutions offers an anatomic facet joint reconstruction device that provides a motion preservation alternative for patients suffering from lumbar spinal stenosis and facet degeneration, distinguishing itself from traditional lumbar spinal fusion methods.

Interlace Medical

Series B in 2008
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Tryton Medical

Series C in 2008
Tryton Medical, Inc. develops stent systems for the treatment of cardiovascular diseases in the United States, Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It offers the Tryton Side Branch Stent System, which offers a strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. The company was founded in 2003 and is based in Durham, North Carolina.

Direct Flow Medical

Series B in 2007
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Barricaid

Series D in 2007
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Leptos Biomedical

Series C in 2007
Leptos Biomedical specializes in a proprietary neuromodulation therapy aimed at treating chronic obesity. Established in 2002 and located in Fridley, Minnesota, the company utilizes a pacemaker-like device to electrically activate a specific nerve within the autonomic nervous system, thereby addressing obesity at a neurological level. This innovative approach seeks to offer an alternative treatment option for individuals struggling with weight management.

Interlace Medical

Series B in 2007
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

PneumRx

Series B in 2007
PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

TearScience

Series B in 2007
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Interlace Medical

Series A in 2006
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Solace Therapeutics

Series B in 2006
Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

Facet Solutions

Series B in 2005
Facet Solutions is a medical device company based in Hopkinton, Massachusetts, established in 2003. The company specializes in developing surgical devices aimed at treating degenerative spinal disorders, particularly those related to facet joints. Facet Solutions offers an anatomic facet joint reconstruction device that provides a motion preservation alternative for patients suffering from lumbar spinal stenosis and facet degeneration, distinguishing itself from traditional lumbar spinal fusion methods.

Direct Flow Medical

Series A in 2005
Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

TearScience

Series A in 2005
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Facet Solutions

Series A in 2004
Facet Solutions is a medical device company based in Hopkinton, Massachusetts, established in 2003. The company specializes in developing surgical devices aimed at treating degenerative spinal disorders, particularly those related to facet joints. Facet Solutions offers an anatomic facet joint reconstruction device that provides a motion preservation alternative for patients suffering from lumbar spinal stenosis and facet degeneration, distinguishing itself from traditional lumbar spinal fusion methods.

Cotherix

Series C in 2003
Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.

Barricaid

Series C in 2002
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Confluent Surgical

Series C in 2002
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Barricaid

Series B in 2001
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Barricaid

Series A in 2000
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.